XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.23.3

Balance Sheets Details | 9 Months Ended
--- | ---
Sep. 30, 2023
Balance Sheets Details [Abstract] |
Balance Sheets Details | Balance Sheets Details Cash Equivalents Cash equivalents as of September 30, 2023 and December 31, 2022, consisted of the following (in thousands):
| September 30, 2023 |  | December 31, 2022
| Adjusted Cost |  | Estimated Fair Value |  | Adjusted Cost |  | Estimated Fair Value
Money market funds (1) | $ | 65,585 |  |  | $ | 65,585 |  |  | $ | 77,309 |  |  | $ | 77,309 |
(1) Money market funds are classified in cash and cash equivalents on our unaudited condensed consolidated balance sheets. Average contractual maturities (in days) is not applicable. As of September 30, 2023, the total cash and cash equivalents balance of $74.6 million consisted of money market funds of $65.6 million and cash of $9.0 million held with major financial institutions. As of December 31, 2022, the total cash and cash equivalents balance of $114.0 million consisted of money market funds of $77.3 million and cash of $36.7 million held with major financial institutions. Inventories Inventories consisted of the following (in thousands):
| September 30, 2023 |  | December 31, 2022
Raw materials | $ | 108 |  |  | $ | 108 |
Work-in-process | — |  |  | 91 |
Finished goods | 2,197 |  |  | 1,830 |
Total Inventories | $ | 2,305 |  |  | $ | 2,029 |
Inventories are recorded net of reserves of $1.4 million as of September 30, 2023 and December 31, 2022. Property and Equipment, net Property and equipment, net consisted of the following (in thousands):
| September 30, 2023 |  | December 31, 2022
Laboratory equipment | $ | 36,376 |  |  | $ | 39,679 |
Leasehold improvements | 11,750 |  |  | 16,633 |
Computer equipment and software | 3,096 |  |  | 3,039 |
Office equipment and furniture | 1,366 |  |  | 1,345 |
Construction in progress | 1,781 |  |  | 1,739 |
Property and equipment | 54,369 |  |  | 62,435 |
Less: accumulated depreciation and amortization | (39,087) |  |  | (39,821) |
Property and equipment, net | $ | 15,282 |  |  | $ | 22,614 |
During the three and nine months ended September 30, 2023, the Company recorded a n on-cash impairment charge of $4.7 million associated with the San Carlos facility leasehold improvements. For additional information, see Note 10, “Commitments and Contingencies.” As of September 30, 2023, the Company had classi fied $2.1 million of laboratory equipment, net of accumulated depreciation, that it intends to sell within the next quarter and that meets the held for sale criteria, to assets held for sale. The Company determined that the carrying value of the assets held for sale exceeds fair value less costs to sell, which resulted in a write-down o f $1.5 million, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the quarter ended September 30, 2023. As of September 30, 2023, the Company has presented $0.6 million of assets held for sale in the condensed consolidated balance sheet. For additional information, see Note 15, “Assets Held For Sale.” Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Depreciation expense | $ | 1,357 |  |  | $ | 1,405 |  |  | $ | 4,302 |  |  | $ | 3,961 |
Goodwill |  |
|  | Goodwill
Balance at January 1, 2023 |  | $ | 3,241 |
Impairment |  | (778) |
Balance at September 30, 2023 |  | $ | 2,463 |
Goodwill was allocated to each of the Company's reporting units. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics. As a result of this plan, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of $0.8 million to write off all of the associated goodwill. The impairment charge is recorded within the asset impairment and other charges in the condensed consolidated statements of operation for the three and nine months ended September 30, 2023. Goodwill had a carrying value of $2.5 million and $3.2 million as of September 30, 2023 and December 31, 2022, respectively. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands):
| September 30, 2023 |  | December 31, 2022
Accrued professional and outside service fees | $ | 5,149 |  |  | $ | 3,495 |
Accrued purchases | 2,644 |  |  | 10,852 |
Other | 1,003 |  |  | 932 |
Total other accrued liabilities | $ | 8,796 |  |  | $ | 15,279 |

X
- Definition -- None. No documentation exists for this element. -- + References No definition available. + Details
Name: | cdxs_BalanceSheetsDetailsAbstract
Namespace Prefix: | cdxs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Balance sheets details. + References No definition available. + Details
Name: | cdxs_BalanceSheetsDetailsTextBlock
Namespace Prefix: | cdxs_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration